Day: May 19, 2020

加拿大滑铁卢, May 19, 2020 (GLOBE NEWSWIRE) — 机器视觉技术的全球领导者，Teledyne Technologies [NYSE:TDY] 公司旗下的 Teledyne DALSA 很高兴宣布推出其第一款短波红外 (SWIR) 线扫描相机，可用于机器视觉。新型 Linea SWIR 具有采用紧凑型封装的先进InGaAs 传感器，适用于各种应用，包括食品和已包装产品的检查、回收、矿物分选以及太阳能和硅片检查。这款最新的 Linea SWIR 线扫描相机具有出色的响应度和低噪声，可让客户以全新的视角观看其产品。Linea SWIR 是一款 1k 分辨率相机，具有高响应度12.5 µm 像素，可实现 40 kHz 行频，同时配备循环模式、可编程 I/O、以太网供电 (PoE)、精确时间协议 (PTP) 等功能。“新款 Linea SWIR 将帮助客户大大提高输出质量。”新款 Linea SWIR 产品经理 Mike Grodzki 说。“Linea SWIR 具有区分材料和检测水分的能力，能够让客户更轻松地识别产品流中的外来污染物。它的成像能力超出可见光谱范围，这一特性使该相机成为食品分选、太阳能晶片检查和消费品包装检查等应用的理想选择。”产品特点：高响应度低噪声 1k 传感器GigE 接口HDR 和循环模式高动态范围可编程 I/O可选择 8 位或 12 位输出平场校正支持 ROI有关 Linea SWIR 的更多信息，请访问网站。要获得高质量图像，请访问我们的在线媒体包。Teledyne DALSA 是 Teledyne Imaging 集团的一部分，在机器视觉市场中是设计、制造和部署数字成像组件的全球领导厂商。Teledyne DALSA 成像传感器、相机、智能相机、图像采集卡、软件和视觉解决方案，广用于全球成千上万台自动检验系统并且跨越多种产业，包括半导体、太阳能电池、平板显示、电子业、汽车业、医疗、包装和一般制造业等。详细请浏览...

Orkla ASA has issued a commercial paper of NOK 200,000,000.Start date:                   25 May 2020Maturity:                      25 June 2020Coupon:                      0.30 %Organised by:             DNB Markets Orkla ASAOslo, 19 May 2020Ref.:Senior Vice President Group TreasuryGeir SolliTel.: +47 995 42 789This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Orkla ASA har emittert et sertifikatlån pålydende NOK 200.000.000,-.Innbetalingsdato:        25. mai 2020Forfall:                         25. juni 2020Kupong                       0,30 %Tilrettelegger:             DNB MarketsOrkla ASAOslo, 19. mai 2020Ref.:Senior Vice President Group TreasuryGeir SolliTlf.: +47 995 42 789Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

RALEIGH, N.C., May 19, 2020 (GLOBE NEWSWIRE) — MobileSmith Health (OTCBB: MOST), a leader in the digital health and mobile development sector that is reshaping traditional healthcare, today announced the launch of the PeriOp Patient Adherence mobile app to support hospitals and health systems as they face the current surge in critical and elective surgeries.“As many states ease the stay-at-home orders impacting millions of Americans, the wave of voluntary and elective surgical procedures is building. Our nation’s hospitals – with strained resources and overstressed frontline workers – must now fight to get back to delivering the high-quality patient care needed for this influx of patients,” said Jerry Lepore, CEO for MobileSmith Health. “This is not the time to be dealing with the financial challenges that come with same-day surgical...

AB “Ignitis gamyba” (hereinafter referred to as the Company and GEN) company code 302648707, registered office at Elektrinės st. 21, Elektrėnai. The total number of registered ordinary shares issued by the Company is 648 002 629; ISIN code LT0000128571.The company informs that on 19 May 2020,  according to the resolutions of the Extraordinary General Meeting of shareholders which was held on 4 December 2019, submitted a request to Nasdaq Vilnius AB to remove the Company’s shares from the official trading list of Nasdaq Vilnius Baltic no later than from 1 July 2020 (the last day of being in the official listing – no later than 30 June 2020).As previously announced (link), the mandatory buyout of GEN shares is being conducted since 18 May 2020. Shareholders of GEN must sell their shares to Ignitis Grupė within 90 calendar days...

AB „Ignitis gamyba“, kodas 302648707, registruotos buveinės adresas Elektrinės g. 21, LT-26108 Elektrėnai, Lietuvos Respublika (toliau – GEN ir Bendrovė). Bendras AB „Ignitis gamyba“ išleistų paprastųjų vardinių akcijų skaičius yra 648 002 629; ISIN kodas – LT0000128571.Bendrovė informuoja, kad 2020 m. gegužės 19 d., įgyvendindama 2019 m. gruodžio 4 d. visuotinio akcininkų susirinkimo sprendimus, pateikė prašymą AB Nasdaq Vilnius išbraukti Bendrovės akcijas iš Nasdaq Vilnius Baltijos oficialiojo prekybos sąrašo ne vėliau kaip nuo 2020 m. liepos 1 d. (paskutinė buvimo oficialiajame prekybos sąraše diena – ne vėliau kaip 2020 m. birželio 30 d.).Kaip jau buvo skelbta anksčiau (nuoroda), nuo 2020 m. gegužės 18 d. yra įgyvendinamas privalomas GEN akcijų išpirkimo procesas. GEN akcininkai jiems priklausančias akcijas „Ignitis grupei“ turi parduoti...

Energijos Skirstymo Operatorius AB (hereinafter – the Company or ESO), identification code 304151376, registered office placed at Aguonu str. 24, Vilnius, Republic of Lithuania. The total number of registered ordinary shares issued by company is 894 630 333; ISIN code LT0000130023. The company informs that on 19 May 2020,  according to the resolutions of the Extraordinary General Meeting of shareholders which was held on 4 December 2019, submitted a request to Nasdaq Vilnius AB to remove the Company’s shares from the official trading list of Nasdaq Vilnius Baltic no later than from 1 July 2020 (the last day of being in the official listing – no later than 30 June 2020). As previously announced (link), the mandatory buyout of ESO shares is being conducted since 18 May 2020. Shareholders of ESO must sell their shares to Ignitis...

AB „Energijos skirstymo operatorius“, kodas 304151376, registruotos buveinės adresas Aguonų g. 24, Vilnius (toliau – Bendrovė arba ESO). Bendras AB „Energijos skirstymo operatorius“ išleistų paprastųjų vardinių akcijų skaičius yra 894 630 333; ISIN kodas – LT0000130023.Bendrovė informuoja, kad 2020 m. gegužės 19 d., įgyvendindama 2019 m. gruodžio 4 d. visuotinio akcininkų susirinkimo sprendimus, pateikė prašymą AB Nasdaq Vilnius išbraukti Bendrovės akcijas iš Nasdaq Vilnius Baltijos oficialiojo prekybos sąrašo ne vėliau kaip nuo 2020 m. liepos 1 d. (paskutinė buvimo oficialiajame prekybos sąraše diena – ne vėliau kaip 2020 m. birželio 30 d.).Kaip jau buvo skelbta anksčiau (nuoroda), nuo 2020 m. gegužės 18 d. yra įgyvendinimas privalomas ESO akcijų išpirkimo procesas. ESO akcininkai jiems priklausančias akcijas „Ignitis grupei“ turi parduoti...

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) — Ogilvy Health, one of Ogilvy’s three global practices (www.ogilvy.com), today announced Nelson Figueiredo, the agency’s VP, Director of Technology, has been named as one of the 2020 PM360 ELITE 100 by healthcare marketing industry trade magazine PM360.  Now in its sixth year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today. The awards honor individuals who have made a significant impact in the life sciences field throughout their careers. Nominees are evaluated based on their accomplishments, testimonials from their clients and colleagues, and supporting evidence that reflects the impact of their efforts. Winners were selected in 18 categories from more than 500 entries extolling the...

Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent developments.Key financial figures and business performance in Q1 2020For the period from January 1 to March 31, 2020, consolidated sales of 6.5 million euros reflect a decrease of 5% compared to the same period last year. This was due to the COVID-19 pandemic, which had a significant negative impact on business development. We experienced the most significant impact of the COVID-19 pandemic in the USA. While we were able to achieve product sales of 4.2 million euros in our largest market in the first quarter, this represents a decline in sales of 19% compared...